Recent share performance and business profile

Novo Nordisk (NYSE:NVO) has drawn investor attention after a mixed stretch for the stock, with the share price down 12.6% year to date yet up 16.5% over the past month.

The Denmark based pharmaceutical group reports US$327.8b in revenue and US$121.96b in net income, primarily from its Diabetes and Obesity Care segment, alongside a smaller Rare Disease business.

At a share price of US$45.80, Novo Nordisk has seen momentum pick up over the past month, with a 30 day share price return of 16.5% partially offsetting a year to date decline of 12.6% and a 1 year total shareholder return decline of 28.5% that points to a more cautious longer term reassessment of the stock.

If Novo Nordisk has you reassessing healthcare exposure, this can be a good moment to broaden your research with other opportunities in the sector via our screener of 34 healthcare AI stocks.

With Novo Nordisk trading at US$45.80, an implied intrinsic discount of 53.7% and only a small gap to the average analyst price target, investors may need to consider whether this reflects a genuine mispricing or whether markets are already factoring in future growth.

Most Popular Narrative: 51.8% Undervalued

At $45.80, the most followed narrative on Simply Wall St, according to bactrian, points to a fair value of $95.00, implying a wide valuation gap.

Novo Nordisk (NVO) has continued to face a tougher near-term backdrop, but the longer-term investment case remains intact. Management has narrowed 2025 guidance to 8 to 11% sales growth and 4 to 7% operating profit growth (constant exchange rates), explicitly citing intensifying competition and pricing pressure in both diabetes and obesity.

Want to understand why this narrative still sees upside potential at almost double today’s price? The argument leans heavily on durable margins, moderated growth assumptions, and a valuation multiple that assumes far less enthusiasm than past market peaks.

Result: Fair Value of $95 (UNDERVALUED)

However, this narrative could be knocked off course if competitive obesity drugs win share faster than expected, or if US pricing reforms bite harder into semaglutide profits.

Next Steps

With mixed sentiment running through this article, now is a good time to review the data yourself, weigh both sides, and see the full picture through 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Novo Nordisk is on your radar, do not stop there. Spreading your research across a few focused lists can help you spot opportunities others might skip.

• Target income first by scanning companies with resilient payout profiles using our list of 13 dividend fortresses.
• Zero in on quality at a discount by reviewing the 48 high quality undervalued stocks that combine strong fundamentals with appealing pricing.
• Stay on the front foot by checking out a 67 resilient stocks with low risk scores that may suit investors who want fewer balance sheet surprises.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.